Business Combinations and Divestments (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||
| Plasma centers acquired from Immunotek | ||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations and Divestments | ||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of detailed information about business combination |
1There is no revaluation of net assets since the fair value of the same does not differ from their carrying value, which was previously recognized in the consolidated financial statements in the context of a joint operation. 2The adjustments resulting from the acquisition relate primarily to the elimination of the net balance payable that the silos maintained with ImmunoTek. Such balances are the accumulated losses from the silos, which are allocated to ImmunoTek in accordance with the terms of the contract. |
|||||||||||||||||||||||||||||||||||||||||||||
| Group 1 centers and Group 2 centers | ||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations and Divestments | ||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of detailed information about business combination |
1There is no step-up of net of assets since the fair value and the carrying amount do no differ significantly. Additionally, the net assets were previously recognized in the consolidated financial statements as part of the joint operation. 2The adjustments resulting from the acquisition correspond mainly to the elimination of the net balance payable that the silos maintained with Immunotek. The net amount represents the accumulated losses from the silos, which were allocated to Immunotek in accordance with the terms of the contract (see note 10) |